期刊文献+

冻干水痘减毒活疫苗安全性及免疫原性观察 被引量:3

Safety and immunogenicity of freeze-dried live attenuated varicella vaccine
原文传递
导出
摘要 目的评价长春祈健生物制品有限公司(简称长春祈健)生产的冻干水痘减毒活疫苗(freeze-dried varicella attenuated live vaccine,VarV-Fd)在3-10岁儿童中的安全性及免疫原性。方法选择2 476名3-10岁的健康儿童,于上臂外侧三角肌附着处经皮下注射VarV-Fd,0.5 ml/(剂·人)。观察局部及全身反应,并采用膜抗原免疫荧光抗体试验(fluorescent antibody to membrane antigen,FAMA)测定免疫前后血清中抗水痘-带状疱疹病毒(varicella zoster virus,VZV)抗体滴度,计算抗体几何平均滴度(GMT)。结果 2 476名观察对象接种疫苗后30 min内均未出现不良反应;接种后7 d内除发热反应(27人)外,未见其他全身反应;仅1人在接种疫苗后第2天出现注射部位红肿(直径为1 cm)的局部反应,未见其他严重不良反应。易感人群免疫后血清的GMT为1∶33.73,抗体阳转率为100%。结论长春祈健生产的VarV-Fd在3-10岁儿童中具有良好的安全性和免疫原性。 Objective To evaluate the safety and immunogenicity of freeze-dried live attenuated varicella vaccine manufactured by Changchun Keygen Biological Products Co., Ltd., Var V-Fd, in children at ages of 3 - 10 years. Methods A total of 2 476 healthy children at ages of 3 - 10 years were injected s. c. with Varv-Fd at a dosage of 0. 5 ml, and observed for local and systemic reactions. The antibody titers against varicella-zoster virus(VZV) in sera of children before and after immunization were determined by fluorescent antibody to membrane antigen(FAMA) test, based on which the GMTs of antibody were calculated. Results No adverse reactions were observed in the 2 476 children within 30 min after vaccination. Except the fever in 27 children within 7 d after vaccination, no other systemic adverse reactions were ob-served. However, except one case of local redness and swelling in injection site on day 2 after vaccination, no other severe local adverse reactions were observed. The GMT of antibody in sera of chilaredn after vaccination was 1 ∶ 33. 19, while the antibody positive rate was 100%. Conclusion Var V-Fd showed high safety and immunogenicity in children at ages of3 - 10 years.
出处 《中国生物制品学杂志》 CAS CSCD 2016年第12期1298-1300,共3页 Chinese Journal of Biologicals
关键词 冻干水痘减毒活疫苗 安全性 免疫原性 Freeze-dried live attenuated varicella vaccine Safety Immunogenicity
  • 相关文献

参考文献2

二级参考文献42

  • 1谢云,李秀玲,刘立新,何薇薇,张中洋,张晨,宋衍燕,陈海平,周铁群.建立膜抗原荧光抗体试验评价北京株冻干水痘疫苗免疫效果[J].微生物学免疫学进展,2005,33(2):6-10. 被引量:6
  • 2金连梅,冯子健.2005-2006年全国水痘疫情分析[J].疾病监测,2007,22(4):251-252. 被引量:106
  • 3Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital [J]. The Lancet, 1974, 2 (7892): 1288-1290.
  • 4Takahashi M, Hayakawa Y, Shiraki K, et al. Attenuation and laboratory markers of the Oka-strain varicella-zoster virus [J]. Postgrad Med J, 1985, 61 (suppl 4): 37-46.
  • 5Johnson CE, Stancin T, Fattlar D, et a/. A long-term pros- pective study of varicella vaccine in healthy children [J]. Pediatrics, 1997, 100 (5): 761-766.
  • 6Wise RP, Salive ME, Braun MM, eta!. Postlicensure safety surveillance for varicella vaccine [J]. JAMA, 2000, 284 (10) : 1271-1279.
  • 7Vessey SJ, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection and vaccine efficacy [J]. J Pediatr, 2001, 139 (2): 297-304.
  • 8Amerrican Academy of Pediatrics, Cimmittee on Infectious Diseases. Varicella vaccine update [J]. Pediatrics, 2000, 105 (1 Pt 1): 136-141.
  • 9WHO. The potential impact of varicella vaccination in low to middle income countries: a feasibility modeling study report to the SAGE working group on varicella and herpes zoster vaccines [EB/OL].(2014-04-05)[2014-12-30]. http: //www. who. int/ immunization / sage / mee-tings / _The potential impact_Vari- cella_vaecination_Low_Middle_Income_Countries_feasibility mo deling, pdf.
  • 10Marin M, Gfiris D, Chaves SS, et ol. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices(ACIP) [J]. MMWR Recomm Rep, 2007, 56(RR-4): 1-40.

共引文献17

同被引文献32

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部